Journal article · 2023 · Open access

Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer: Findings From a Multicountry Survey

Fátima Cardoso, Julie Rihani, Victoria Harmer, Nadia Harbeck, Ana Casas, Hope S. Rugo, Peter Andreas Fasching, Adam Moore, Joanna de Courcy, Purnima Pathak, Sina Haftchenary, Dawn Aubel and 1 more

The Oncologist, 28(10), 856–865 · Published 31 July 2023 · DOI 10.1093/oncolo/oyad207

Open PDFView at the publisherCite this paper

In brief

“Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer: Findings From a Multicountry Survey” is a 2023 journal article by Fátima Cardoso and 12 co-authors, published in The Oncologist. OpenAlex counts 30 citations as of 22 November 2026, which puts it in the top 2% of works published in 2023 by citations. It is open access under a CC BY-NC licence: the full text is free to read at The Oncologist.

Citations
30
Most cited in
2025 (13)
Field-weighted impact
3.27
References
48
Authors
13

Abstract

BACKGROUND: Quality of life (QOL) is a critical factor in decision-making for advanced breast cancer (ABC). There is a need to improve how QOL and treatment-related side effects (SEs) that impact it are clinically assessed. We examined healthcare professionals' (HCPs') and patients' perspectives on the importance of QOL discussions and the impact of SEs on QOL in clinical settings. PATIENTS AND METHODS: A cross-sectional online survey was conducted (7/2020-5/2021) among oncologists, nurses, and patients with HR+/HER2- ABC in 7 countries. RESULTS: The survey was completed by 502 HCPs and 467 patients. Overall, 88% of oncologists and 49% of patients recalled QOL discussions at follow-up. In the first- through fourth-line (1L, 2L, 3L, and 4L) settings, respectively, 48%, 57%, 79%, and 85% of oncologists reported QOL was very important; 73% and 45% of patients receiving 1L and 2L treatment and 40% receiving 3L+ treatment indicated QOL was important. Patients reported that insomnia, anxiety, back pain, fatigue, diarrhea, hot flashes, low sexual interest, and loss of appetite had a moderate/severe impact on QOL. Of patients experiencing certain SEs, ≥64% did not discuss them with HCPs until there was a moderate/severe impact on QOL. In patients receiving a CDK4/6 inhibitor, SEs, including insomnia, diarrhea, back pain, and fatigue, had a moderate/severe impact on QOL. CONCLUSIONS: This survey discovered disconnects between HCPs and patients with ABC on the importance of QOL discussions and the impact of SEs on QOL. These data support the use of ABC-specific QOL questionnaires that closely monitor SEs impacting QOL.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Cardoso, F., Rihani, J., Harmer, V., Harbeck, N., Casas, A., Rugo, H. S., Fasching, P. A., Moore, A., de Courcy, J., Pathak, P., Haftchenary, S., Aubel, D., & Schumacher-Wulf, E. (2023). Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer: Findings From a Multicountry Survey. The Oncologist, 28(10), 856–865. https://doi.org/10.1093/oncolo/oyad207

MLA 9

Cardoso, Fátima, et al. “Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer: Findings From a Multicountry Survey.” The Oncologist, vol. 28, no. 10, 2023, pp. 856–865. https://doi.org/10.1093/oncolo/oyad207.

Chicago

Cardoso, Fátima, Julie Rihani, Victoria Harmer, Nadia Harbeck, Ana Casas, Hope S. Rugo, Peter Andreas Fasching, et al. 2023. “Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer: Findings From a Multicountry Survey.” The Oncologist 28 (10): 856–865. https://doi.org/10.1093/oncolo/oyad207.

Harvard

Cardoso, F. et al. (2023) ‘Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer: Findings From a Multicountry Survey’, The Oncologist, 28(10), pp. 856–865. doi:10.1093/oncolo/oyad207.

IEEE

F. Cardoso et al., “Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer: Findings From a Multicountry Survey,” The Oncologist, vol. 28, no. 10, pp. 856–865, 2023, doi: 10.1093/oncolo/oyad207.

BibTeX

@article{cardoso2023quality,
  title     = {{Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer: Findings From a Multicountry Survey}},
  author    = {Cardoso, Fátima and Rihani, Julie and Harmer, Victoria and Harbeck, Nadia and Casas, Ana and Rugo, Hope S. and Fasching, Peter Andreas and Moore, Adam and de Courcy, Joanna and Pathak, Purnima and Haftchenary, Sina and Aubel, Dawn and Schumacher-Wulf, Eva},
  journal   = {The Oncologist},
  year      = {2023},
  volume    = {28},
  number    = {10},
  pages     = {856--865},
  doi       = {10.1093/oncolo/oyad207},
  url       = {https://doi.org/10.1093/oncolo/oyad207}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202477
20251313
20261010

Its field-weighted citation impact is 3.27: it has been cited 3.27 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Oncology › Cancer survivorship and care

  • quality of life
  • treatment side effects
  • hormone receptor-positive HER2-negative breast cancer
  • advanced breast cancer
  • patient-physician communication
  • CDK4/6 inhibitors
  • insomnia
  • fatigue

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Cardoso, F., Rihani, J., Harmer, V., Harbeck, N., Casas, A., Rugo, H. S., Fasching, P. A., Moore, A., de Courcy, J., Pathak, P., Haftchenary, S., Aubel, D., & Schumacher-Wulf, E. (2023). Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer: Findings From a Multicountry Survey. The Oncologist, 28(10), 856–865. https://doi.org/10.1093/oncolo/oyad207

How many times has this paper been cited?

30 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at The Oncologist: sign in and open the PDF from this page.

Who wrote this paper?

Fátima Cardoso, Julie Rihani, Victoria Harmer, Nadia Harbeck, Ana Casas, Hope S. Rugo, Peter Andreas Fasching, Adam Moore, Joanna de Courcy, Purnima Pathak, Sina Haftchenary, Dawn Aubel and 1 more.

What is the DOI of this paper?

10.1093/oncolo/oyad207, permanently at https://doi.org/10.1093/oncolo/oyad207. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.